| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Director | Executive Vice President & CFO
3 companies
Jonathan P. Foster is Chief Financial Officer at MBRX and has filed Form 4s across 3 companies. Jonathan P. Foster's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.8M at current prices.
Historically, Jonathan P. Foster's trades have earned a below-average insider score of 27/100 across 3 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -70.8%.
The biggest single holding is MBRX (~$3.4M) as Chief Financial Officer. Net of sales, the MBRX filings show accumulation of 602,589 shares.
Jonathan P. Foster has 32 Form 4 filings on record from March 2015 to October 2026, across 3 companies: Chief Financial Officer at Moleculin Biotech (MBRX), 2016–2026; Director at Empery Digital (EMPD), 2022–2026; Chief Financial Officer at InfuSystem (INFU), 2015.
The 61 reported transactions were 21 option or other derivative awards, 14 option exercises, 12 tax withholdings and 9 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $146K and no sales.
The largest open-market purchase was 270,270 shares of MBRX at an average $0.37 on June 23, 2025, about $100K. Twelve months later MBRX was down 60%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | MBRX Moleculin Biotech, Inc. | Chief Financial Officer | Buy | 293,333 | $0.00 | - | +2,377% | +2.6% | - | |
| Jun 23, 2025 | MBRX Moleculin Biotech, Inc. | Chief Financial Officer | Buy | 270,270 | $0.37 | $99,999.90 | +1,561% | +49.0% | -59.8% | |
| Dec 26, 2023 | MBRX Moleculin Biotech, Inc. | Chief Financial Officer | Buy | 28,986 | $0.69 | $20,000.34 | +56.2% | -46.0% | -81.8% | |
| Apr 25, 2017 | MBRX Moleculin Biotech, Inc. | Executive Vice President & CFO | Buy | 10,000 | $0.86 | $8,649.00 | New | - | - | |
| Aug 18, 2015 | INFU Infusystem Holdings, Inc | Chief Financial Officer | Buy | 1,000 | $2.92 | $2,920.00 | +3.6% | - | - | |
| Jun 15, 2015 | INFU Infusystem Holdings, Inc | Chief Financial Officer | Buy | 312 | $3.12 | $973.44 | New | - | - | |
| May 15, 2015 | INFU Infusystem Holdings, Inc | Chief Financial Officer | Buy | 4,270 | $3.07 | $13,108.90 | +23.3% | - | - |